Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yibing Yan

Showing results (61-70 of 89) with videos related to

Pageof 9
Sort By:
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus VemurafenibMatthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
Cell Death and Differentiation|March 3, 2019
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptationJason E Long, Matthew J Wongchenko, Dorothee Nickles, et al.
Blood|September 2, 2011
Critical role for Syk in responses to vascular injuryPatrick Andre, Toshifumi Morooka, Derek Sim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic MelanomaYibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Journal of Translational Medicine|March 26, 2013
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myelomaCongfen Li, Chikara Takahashi, Liangxuan Zhang, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
Pageof 9

Showing results (61-70 of 89) with videos related to

Sort By:
Pageof 9
Nature Medicine|June 8, 2019
Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patientsRyan J Sullivan, Omid Hamid, Rene Gonzalez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 25, 2017
Gene Expression Profiling in <i>BRAF</i>-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus VemurafenibMatthew J Wongchenko, Grant A McArthur, Brigitte Dréno, et al.
The Lancet. Oncology|December 2, 2022
Overall survival with first-line atezolizumab in combination with vemurafenib and cobimetinib in BRAF<sup>V600</sup> mutation-positive advanced melanoma (IMspire150): second interim analysis of a multicentre, randomised, phase 3 studyPaolo A Ascierto, Daniil Stroyakovskiy, Helen Gogas, et al.
Cell Death and Differentiation|March 3, 2019
Therapeutic resistance and susceptibility is shaped by cooperative multi-compartment tumor adaptationJason E Long, Matthew J Wongchenko, Dorothee Nickles, et al.
Blood|September 2, 2011
Critical role for Syk in responses to vascular injuryPatrick Andre, Toshifumi Morooka, Derek Sim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2019
Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with <i>BRAF</i> <sup>V600</sup>-mutated Metastatic MelanomaYibing Yan, Matthew J Wongchenko, Caroline Robert, et al.
Journal of Translational Medicine|March 26, 2013
Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myelomaCongfen Li, Chikara Takahashi, Liangxuan Zhang, et al.
Nature Communications|May 9, 2025
Ligand-activated EGFR/MAPK signaling but not PI3K, are key resistance mechanisms to EGFR-therapy in colorectal cancerXueping Qu, Habib Hamidi, Radia M Johnson, et al.
Journal of the National Cancer Institute|March 29, 2013
P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanomaChristy C Ong, Adrian M Jubb, Diana Jakubiak, et al.
Investigational New Drugs|April 26, 2019
Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumorsGeoffrey I Shapiro, Patricia LoRusso, Eunice Kwak, et al.
Pageof 9